202 related articles for article (PubMed ID: 19048595)
1. Identification of Fat4 as a candidate tumor suppressor gene in breast cancers.
Qi C; Zhu YT; Hu L; Zhu YJ
Int J Cancer; 2009 Feb; 124(4):793-8. PubMed ID: 19048595
[TBL] [Abstract][Full Text] [Related]
2. Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway.
Li SY; Wang H; Mai HF; Li GF; Chen SJ; Li GS; Liang BC
Cancer Gene Ther; 2019 Nov; 26(11-12):374-387. PubMed ID: 30546116
[TBL] [Abstract][Full Text] [Related]
3. FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β-catenin activity in ovarian cancer.
Malgundkar SH; Burney I; Al Moundhri M; Al Kalbani M; Lakhtakia R; Okamoto A; Tamimi Y
BMC Cancer; 2020 May; 20(1):374. PubMed ID: 32366234
[TBL] [Abstract][Full Text] [Related]
4. FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt/β-catenin signalling.
Cai J; Feng D; Hu L; Chen H; Yang G; Cai Q; Gao C; Wei D
Br J Cancer; 2015 Dec; 113(12):1720-9. PubMed ID: 26633557
[TBL] [Abstract][Full Text] [Related]
5. Fat4 suppression induces Yap translocation accounting for the promoted proliferation and migration of gastric cancer cells.
Ma L; Cui J; Xi H; Bian S; Wei B; Chen L
Cancer Biol Ther; 2016; 17(1):36-47. PubMed ID: 26575609
[TBL] [Abstract][Full Text] [Related]
6. Function and cancer genomics of FAT family genes (review).
Katoh M
Int J Oncol; 2012 Dec; 41(6):1913-8. PubMed ID: 23076869
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory mechanism of FAT4 gene expression in response to actin dynamics during Src-induced carcinogenesis.
Ito T; Taniguchi H; Fukagai K; Okamuro S; Kobayashi A
PLoS One; 2015; 10(2):e0118336. PubMed ID: 25679223
[TBL] [Abstract][Full Text] [Related]
8. The novel FAT4 activator jujuboside A suppresses NSCLC tumorigenesis by activating HIPPO signaling and inhibiting YAP nuclear translocation.
Wang W; Huang Q; Chen Y; Huang Z; Huang Y; Wang Y; Qi X; Liu Z; Lu L
Pharmacol Res; 2021 Aug; 170():105723. PubMed ID: 34116210
[TBL] [Abstract][Full Text] [Related]
9. A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors.
Mao W; Zhou J; Hu J; Zhao K; Fu Z; Wang J; Mao K
Front Public Health; 2022; 10():969070. PubMed ID: 36051999
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of FAT4 contributes to gastric field cancerization.
Yoshida S; Yamashita S; Niwa T; Mori A; Ito S; Ichinose M; Ushijima T
Gastric Cancer; 2017 Jan; 20(1):136-145. PubMed ID: 26792292
[TBL] [Abstract][Full Text] [Related]
11. Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer.
Yin X; Xiang T; Mu J; Mao H; Li L; Huang X; Li C; Feng Y; Luo X; Wei Y; Peng W; Ren G; Tao Q
Oncotarget; 2016 Aug; 7(32):51720-51732. PubMed ID: 27351130
[TBL] [Abstract][Full Text] [Related]
12. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
[TBL] [Abstract][Full Text] [Related]
13. FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis.
Wei R; Xiao Y; Song Y; Yuan H; Luo J; Xu W
J Exp Clin Cancer Res; 2019 Mar; 38(1):112. PubMed ID: 30832706
[TBL] [Abstract][Full Text] [Related]
14. Comparative epigenomics of human and mouse mammary tumors.
Demircan B; Dyer LM; Gerace M; Lobenhofer EK; Robertson KD; Brown KD
Genes Chromosomes Cancer; 2009 Jan; 48(1):83-97. PubMed ID: 18836996
[TBL] [Abstract][Full Text] [Related]
15. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor function of RUNX3 in breast cancer.
Chen LF
J Cell Biochem; 2012 May; 113(5):1470-7. PubMed ID: 22275124
[TBL] [Abstract][Full Text] [Related]
17. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer.
Yu JS; Koujak S; Nagase S; Li CM; Su T; Wang X; Keniry M; Memeo L; Rojtman A; Mansukhani M; Hibshoosh H; Tycko B; Parsons R
Oncogene; 2008 Aug; 27(34):4657-65. PubMed ID: 18408767
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
19. Mammary differentiation induces expression of Tristetraprolin, a tumor suppressor AU-rich mRNA-binding protein.
Goddio MV; Gattelli A; Slomiansky V; Lacunza E; Gingerich T; Tocci JM; Facchinetti MM; Curino AC; LaMarre J; Abba MC; Kordon EC
Breast Cancer Res Treat; 2012 Oct; 135(3):749-58. PubMed ID: 22968621
[TBL] [Abstract][Full Text] [Related]
20. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
